Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort.
Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort.
复制标题
加州教师研究队列中女性的乳房植入物和间变性大细胞淋巴瘤。
DOI:
10.1111/bjh.13779
复制
发表时间:
2016
影响因子:
6.5
通讯作者:
Bernstein,Leslie
中科院分区:
文献类型:
--
作者:
Wang,SophiaS;Deapen,Dennis;Voutsinas,Jenna;LaceyJr,JamesV;Lu,Yani;Ma,Huiyan;Clarke,ChristinaA;Weisenburger,Dennis;Forman,StephenJ;Bernstein,Leslie
Clinical case series have reported an apparent coexistence of breast implants and primary T-cell lymphomas of the breast, specifically for the anaplastic large cell lymphoma (ALCL) subtype (Gidengil et al 2015; Jewell et al 2011; Thompson & Prince 2013). In 2011, the Food and Drug Administration (FDA) reported a “possible association between breast implants and the development of ALCL” and encouraged “additional evaluation from other studies”(United States Food and Drug Administration 2011), particularly as epidemiological data have not yielded consistent results. A review of five prospective cohort studies comprising> 43,000 women with cosmetic breast implants followed for up to 37 years found no excess ALCL risk (Lipworth et al 2008). Data from a Danish cohort of approximately 20,000 women with breast implants identified 31 lymphomas, but no ALCLs Vase et al 2013). Another study of> 150,000 women with breast implants identified 3 breast ALCL, which was lower than expected based on cancer registry data [Spear et al (2010)]. However, a case-control study nested within the population-based cancer registry in the Netherlands with case ascertainment from 1994-2006, reported an association between silicone breast implants and ALCL (Odds Ratio [OR]= 18.2, 95% Confidence Interval [CI]= 2.1-156.8, based on 11 ALCLs).